ZYDUSLIFE
Zydus Lifesciences Limited (ZYDUSLIFE) Stock Analysis
Zydus Lifesciences Limited is a major Indian pharmaceutical company developing and manufacturing generics, biosimilars, and innovative medicines. It has a global footprint in the US, India, and emerging markets with strengths in vaccines and complex injectables. The company was formerly Cadila Healthcare. It is listed on the NSE and BSE.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,117.50
-2.46% 1W | +15.90% 52W
Market Cap
111.5k CR
P/E Ratio
24.9
52W High
₹1232.1
52W Low
₹835.5
Div. Yield
0.09%
Beta
0.4
50 DMA
₹1144.5
200 DMA
₹1017.5
Profit Margin
15.8%
Inst. Own.
16.2%
⚡ APPROACHING SUPPORT
⚡ APPROACHING SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,140 | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 |
| Expenses | 3,634 | 3,223 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 | 6,088 |
| Operating Profit | 1,505 | 1,146 | 1,102 | 1,630 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 |
| OPM % | 29% | 26% | 24% | 29% | 34% | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% |
| Other Income | 21 | 53 | 60 | 160 | 63 | 68 | 57 | -139 | 155 | 75 | 26 | -263 | 88 |
| Interest | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 |
| Depreciation | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 |
| Profit before tax | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 |
| Tax % | 16% | 22% | 23% | 21% | 23% | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 27% |
| Net Profit | 1,134 | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| EPS in Rs | 10.74 | 7.91 | 7.80 | 11.75 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.42 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 | 28,592 |
| Expenses | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,758 | 11,923 | 13,378 | 14,163 | 16,183 | 18,673 | 20,276 |
| Operating Profit | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,344 | 3,342 | 3,860 | 5,384 | 7,058 | 8,475 | 8,316 |
| OPM % | 20% | 25% | 20% | 24% | 23% | 20% | 22% | 22% | 22% | 28% | 30% | 31% | 29% |
| Other Income | 45 | 112 | 127 | 111 | 183 | -264 | -171 | 2,581 | -422 | 293 | 50 | -7 | -74 |
| Interest | 68 | 53 | 45 | 91 | 194 | 342 | 164 | 127 | 130 | 81 | 166 | 439 | 510 |
| Depreciation | 287 | 292 | 373 | 539 | 599 | 696 | 725 | 713 | 723 | 764 | 916 | 1,408 | 1,725 |
| Profit before tax | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,285 | 5,084 | 2,585 | 4,832 | 6,027 | 6,621 | 6,007 |
| Tax % | 18% | 8% | 8% | 24% | 22% | 21% | 6% | 10% | 23% | 20% | 23% | 24% | |
| Net Profit | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 | 4,593 |
| EPS in Rs | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 | 44.97 | 50.09 | 44.94 |
| Dividend Payout % | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% | 31% | 8% | 24% | 2% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 16.0% | 12.0% | 11.0% |
| Profit CAGR | 32.0% | 19.0% | 11.0% |
Shareholding Pattern
Promoters75.00%
FIIs7.34%
DIIs10.86%
Public6.81%
Promoters75.00%
FIIs7.06%
DIIs11.08%
Public6.86%
Promoters75.00%
FIIs6.95%
DIIs11.20%
Public6.86%
Promoters75.02%
FIIs6.89%
DIIs11.27%
Public6.83%
Promoters75.01%
FIIs7.05%
DIIs11.28%
Public6.66%
Promoters74.98%
FIIs3.42%
DIIs13.51%
Public8.01%
Promoters74.98%
FIIs5.72%
DIIs12.55%
Public6.66%
Promoters75.00%
FIIs7.31%
DIIs10.95%
Public6.69%
Promoters75.00%
FIIs6.95%
DIIs11.20%
Public6.86%
Promoters75.01%
FIIs7.05%
DIIs11.28%
Public6.66%
ZYDUSLIFE
Holdings Analysis
Key strengths & risk signals
75
Overall
87
Fundamental
63
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.09% yield - little to no income.
RECOVERY MODE! Current price (1117.5) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.5% (1 week), 0.9% (1 month), 2.9% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.67 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (1144.5) is above 200-day average (1017.5) - positive signal.
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
UPPER HALF! Trading at 71.1% of 52W range - positive territory.
Fundamental & Technical Analysis
75Overall
87Fundamental
63Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 16.5% (VERY GOOD, 13/15). Profit CAGR: 37.0% (EXCELLENT, 15/15).
Profit Margin
6/10
GOOD EFFICIENCY! 15.8% profit margin - above average profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.67 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.09% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.12 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 7.47% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1144.5) is above 200-day average (1017.5) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1117.5) above 200-day but below 50-day.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
6/10
POSITIVE YEAR! Stock gained 15.9% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 1,655,392 vs down days: 1,430,418. Ratio: 1.16x
RSI
3/5
NEUTRAL! RSI at 42.4 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 71.1% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.5% (1 week), 0.9% (1 month), 2.9% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
ZYDUSLIFE
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-24 | Concall PDF | |
| Q3FY262026-02-15 | Concall PDF | |
| Q2FY262025-11-13 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYDUSLIFE | ₹1,117.50 | 24.9 | 15.8% | 16.5% | 37.0% | +15.9% | 75 | APPROACHING SUPPORT | -35.9% | -26.1% | +20.6% | +4.9% |
| LAURUSLABS | ₹2,036.60 | 100.7 | 15.0% | 3.8% | 4.0% | +127.9% | 55 | CONSOLIDATING UP | +125.5% | +31.7% | +29.1% | +11.9% |
| CIPLA | ₹1,301.00 | 31.2 | 12.0% | 7.2% | 11.5% | -16.3% | 60 | APPROACHING SUPPORT | -39.2% | +42.3% | +3.5% | +9.5% |
| DRREDDY | ₹1,197.00 | 30.1 | 10.0% | 11.0% | -1.7% | -3.4% | 63 | BREAKOUT | -68.7% | +100.8% | -5.6% | +7.4% |
| MANKIND | ₹2,368.50 | 47.9 | 13.9% | 17.7% | 14.3% | -3.2% | 70 | APPROACHING SUPPORT | +29.6% | +2.5% | +12.9% | +17.1% |
| AUROPHARMA | ₹1,693.00 | 26.5 | 10.6% | 10.7% | 22.1% | +45.5% | 81 | APPROACHING RESISTANCE | +25.2% | +12.1% | +16.9% | +4.0% |
| LUPIN | ₹1,956.50 | 16.2 | 18.5% | 19.1% | 131.5% | -1.1% | 65 | BREAKDOWN | +16.1% | -3.1% | +33.3% | +11.2% |
| GLENMARK | ₹2,293.00 | 34.6 | 10.1% | 13.5% | 66.1% | +17.7% | 69 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
Data from TradeAlone · Updated daily
ZYDUSLIFE News
Zydus Lifesciences Limited Launches First Generic of Adempas® in the U.S.2026-10-05Zydus Lifesciences Limited (zyduslife) USFDA Inspection Concludes at Ahmedabad Plant2026-09-28Zydus Lifesciences Limited (zyduslife) USFDA Inspection of Pharmacovigilance Concludes with Nil Observations2026-09-26Zydus Lifesciences Limited (zyduslife) Announces Positive Topline Results from Completed Evidences-x Phase Ii(b) Clinical Trial of Saroglitazar Mg in MASH2026-08-31Zydus Lifesciences Limited (zyduslife) Secures Final USFDA Approval for Ascorbic Acid Injection2026-08-21Zydus Lifesciences Limited (zyduslife) Partners with Mereo Biopharma for Alvelestat in Rare Lung Disease2026-08-11Zydus Lifesciences Limited (ZYDUSLIFE) gains 5% intraday, nears resistance2026-08-11Zydus Lifesciences Limited Q1 FY27: Revenues Surge 22% Yoy2026-08-11Zydus Lifesciences Limited (zyduslife) Launches Revahale™, India’s First Once-daily Nebulised LAMA for COPD2026-08-10Zydus Lifesciences Limited (zyduslife) Secures Final Approval from USFDA for Indocyanine Green for Injection2026-08-04Zydus Lifesciences Limited (zyduslife) Receives EIR from USFDA for Injectable Facility with VAI Classification2026-08-01Zydus Lifesciences Limited (zyduslife) Receives Approval for Phase III Trial of Desidustat in Sickle Cell Disease Patients2026-07-23Zydus Lifesciences Limited (zyduslife) Signs Mou with Apollo Hospitals to Expand Access to Shield™ Multi-cancer Detection Test2026-07-03Zydus Lifesciences Limited Announces Successful Completion of Acquisition of Assertio Holdings2026-06-16Zydus Lifesciences Limited (zyduslife) NDA for Saroglitazar Granted Priority Review by US FDA2026-05-28
